Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)

Hims & Hers Health (HIMS) reported Q3 results, leading to a significant stock decline of 13% over five days and 27% QTD, attributed to an earnings miss and a lowered FY outlook of $2.335B-$2.355B. Despite this, the company demonstrated positive operational trends, with subscriber growth up 21% year-over-year to 2.5 million and monthly online revenue per subscriber increasing to $80, largely driven by personalized treatment plans, including compounded weight-loss drugs. Analysts are upgrading the stock, noting that negatives are now priced in, and highlighting potential catalysts such as active discussions with Novo Nordisk for Wegovy, international expansion through the ZAVA acquisition and Canadian launch, and diversification into men's health, though the stock is still considered a short-term trade.

Analysis

Hims & Hers Health (HIMS) experienced a significant market sell-off following its Q3 earnings report, with the stock declining 13% over five days and 27% quarter-to-date, reaching $41 from an October high of $62.78. This downturn was exacerbated by an earnings miss and a lowered FY outlook to $2.335B-$2.355B. However, analysts, previously bearish due to the Novo Nordisk partnership termination, now suggest that these negatives are largely priced in, leading to an upgrade to a "buy" rating.

Despite the market reaction, HIMS demonstrated operational resilience, with subscriber count increasing 21% year-over-year to 2.5 million and monthly online revenue per subscriber recovering to $80 from $74 last quarter. This recovery is attributed to the successful adoption of personalized treatment plans, which grew 50% year-over-year, facilitating the sale of compounded GLP-1 weight-loss drugs. The company is also in "active discussions" with Novo Nordisk for a potential Wegovy partnership, which could capitalize on the projected 18.54% GLP-1 market CAGR.

HIMS is actively diversifying its growth avenues beyond weight-loss drugs, including international expansion through the acquisition of European digital health platform ZAVA and a planned launch in Canada. Additionally, the company entered the men's health market with low testosterone treatments and plans further expansion with FDA-approved therapies like Kyzatrex. These initiatives aim to offset potential uncertainties in the weight-loss drug segment and leverage the personalized healthcare model.

Key Decisions for Investors

• Investors should consider HIMS for short-term trading, acknowledging the analyst upgrade and the belief that recent negatives are priced in, aligning with its "trade over investment" characterization.
• Closely monitor developments regarding the potential Novo Nordisk partnership and the market's response to GLP-1 price reductions, as these are significant near-term catalysts for the weight-loss segment.
• Assess the successful integration of the ZAVA acquisition and the performance of new market entries, including Canada and men's health offerings, as these represent crucial diversification and growth drivers.